Merck & Co., Inc. Market Research Report
Company Overview
Name: Merck & Co., Inc.
Mission: We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.
Founded: January 1, 1891, by George Merck
Key People:
- Rob Davis - Chairman and Chief Executive Officer
- Dr. Dean Li - President, Merck Research Laboratories
- Jennifer Zachary - General Counsel
- Caroline Litchfield - Chief Financial Officer
- Cristal Downing - Recognized as an influential woman executive
Headquarters: 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065 USA
Number of Employees: Approximately 21,800 employees in R&D
Revenue: No information is available
Known For: Merck is known for its innovative medicines and vaccines for diseases such as cancer, HIV, HPV-related cancers, COVID-19, and many others. The company also has a strong commitment to sustainability and health equity.
Products
Pharmaceuticals
- JANUMET®: Tablets for oral use to treat diabetes.
- KEYTRUDA®: Injection for intravenous use for various cancers.
- LYNPARZA®: Tablets for oral use for lung and other cancers.
Vaccines
- GARDASIL®: HPV vaccine to prevent cervical and other cancers.
- M-M-R® II: Measles, Mumps, and Rubella Virus Vaccine Live.
- VAXNEUVANCE®: Pneumococcal 15 valent conjugate vaccine.
Anti-Infectives
- ISENTRESS®: Tablets for oral use for HIV treatment.
- CUBICIN®: Daptomycin for injection, for intravenous use to treat bacterial infections.
High-Level Description and Key Features:
1. KEYTRUDA® (Pembrolizumab):
- Description: A monoclonal antibody for intravenous use to treat various cancers.
- Key Features: Effective in treating non-small cell lung cancer, melanoma, and other malignancies. Has breakthrough therapy designation.
2. GARDASIL®:
- Description: HPV vaccine to prevent cervical cancer and other cancers caused by HPV.
- Key Features: Quadrivalent vaccine targeting four types of HPV.
3. LYNPARZA®:
- Description: A PARP inhibitor for the treatment of certain types of cancers including ovarian and prostate cancer.
- Key Features: Used in combination with other therapies for enhanced efficacy.
Recent Developments
New Products Launched:
- CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine): Recently rolled out, further details on regions are under review.
New Features Added to Existing Products:
- KEYTRUDA®: Expanded indications including advanced solid tumors and mesothelioma.
New Partnerships:
- Daiichi Sankyo and Merck: Entered into a global development and commercialization agreement for MK-6070.
- Merck B-Chemotherapy: Acquired investigational B-cell depletion therapy, CN201, from Curon Biopharmaceutical.
Notable Developments:
- Phase 3 Trials Initiated for Bomedemstat: Investigational candidate for treatment of certain patients with essential thrombocythemia.
- European Commission Approval for WINREVAIR™: Approval received for sotatercept in combination with other pulmonary arterial hypertension therapies for adults.
Clinical Trials:
- IDeate-Lung02 Phase 3 Trial: Initiated for Ifinatamab Deruxtecan in patients with relapsed small cell lung cancer.
- Approval and Trials for LAGEVRIO™: Approved for COVID-19 treatment in the US, with ongoing trials for broader applications.
Cultural and Values Commitment
- Patients First: Accountability for delivering high-quality products and services.
- Respect for People: Ethics and integrity in operations.
- Innovation and Scientific Excellence: Commitment to break through research and development.
Sustainability Efforts
- Impact Report 2023/2024: Emphasis on operating responsibly to ensure a sustainable future.
- Diversity and Inclusion: Embedded culture of inclusion, with 45% women in management roles.
- Environmental Goals: Target for net-zero emissions by 2045.
Conclusion
Merck & Co., Inc. continues to prioritize innovative research and development, focusing on delivering breakthrough medicines and vaccines. Their sustainability and health equity initiatives position them as a leader in the biopharmaceutical industry.
